Showing results (11-20 of 109) with videos related to
Sort By:
Pageof 11
Annales Chirurgiae Et Gynaecologiae|January 1, 1989
Tumour markers in pancreatic cancerC Haglund, P Kuusela, P J RobertsThe American Journal of Surgical Pathology|October 31, 2001
Increased expression of tenascin in pheochromocytomas correlates with malignancyK Salmenkivi, C Haglund, J Arola, et al.Oncology|January 17, 2008
Tenascin-C expression and its prognostic significance in colorectal cancerM Lundin, S Nordling, J Lundin, et al.European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|February 1, 1994
Large mesenteric mass caused by a mesenteric desmoid tumourL Halme, C Haglund, S Nordling, et al.Scandinavian Journal of Clinical and Laboratory Investigation|May 1, 1991
Tumour marker CA 125 in patients with digestive tract malignanciesC Haglund, P Kuusela, P Roberts, et al.Clinical Biochemistry|June 1, 1995
Enzyme immunoassay for quantification of tenascin in biologic samplesS Ylätupa, P Mertaniemi, C Haglund, et al.Journal of Immunological Methods|July 6, 1993
Competitive enzyme immunoassay for quantification of the cellular form of fibronectin (EDAcFN) in blood samplesS Ylätupa, P Partanen, C Haglund, et al.Clinica Chimica Acta; International Journal of Clinical Chemistry|January 31, 1995
An improved method for quantification of extra domain A-containing cellular fibronectin (EDAcFN) in different body fluidsS Ylätupa, P Mertaniemi, C Haglund, et al.British Journal of Cancer|January 1, 1997
Cellular fibronectin concentration in the plasma of patients with malignant and benign diseases: a comparison with CA 19-9 and CEAC Haglund, S Ylätupa, P Mertaniemi, et al.Scandinavian Journal of Gastroenterology. Supplement|January 1, 1986
Tumour markers in pancreatic cancerC Haglund, P J Roberts, P Kuusela, et al.Pageof 11